Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): Recommendations of the German GIST Imaging Working Group

Cancer Imaging

Volumn 12, Issue 1, 2012, Pages 126-135

  Kalkmann, Janine ^a   Zeile, Martin ^b   Antoch, Gerald ^c   Berger, Frank ^d   Diederich, Stefan ^e   Dinter, Dietmar ^f   Fink, Christian ^f   Janka, Rolf ^g   Stattaus, Jörg ^h  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Hospital Reinbek St Adolf Stift   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e MARIEN HOSPITAL DÜSSELDORF   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Choi criteria; Gastrointestinal stromal tumour; Imaging; RECIST; Staging; Therapy response

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IMATINIB; NONIONIC CONTRAST MEDIUM; SCOPOLAMINE BUTYL BROMIDE; SUNITINIB;

ABDOMEN; ARTICLE; CANCER REGRESSION; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MYXOID DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; RADIOLOGIST; SINGLE DRUG DOSE; TISSUE DEGENERATION; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR VOLUME;

ALGORITHMS; ARTIFACTS; CONTRAST MEDIA; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862162325     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.0013     Document Type: Article

References (40)

1. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Human Pathol 2001; 32: 578-82. doi:10.1053/hupa.2001.25484. (Pubitemid 32601238)
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12. doi:10.1007/ s004280000338. (Pubitemid 32128184)
3. Chourmouzi D, Sinakos E, Papalavrentios L, Akriviadis E, Drevelegas A. Gastrointestinal stromal tumors: a pictorial review. J Gastrointest Liver Dis 2009; 18: 379-83.
4. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comprehensive Cancer Network 2010; 8(Suppl 2): S1-41; quiz S42-4.
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6. doi:10.1056/NEJM200104053441404. (Pubitemid 32267975)
6. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002; 179: 1059-62.
7. Stroszczynski C, Jost D, Reichardt P, et al. Follow-up of gastrointestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. Eur Radiol 2005; 15: 2448-56. doi:10.1007/s00330-005-2867-x. (Pubitemid 43153845)
8. Shankar S, van Sonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235: 892-8. doi:10.1148/radiol.2353040332. (Pubitemid 40695886)
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi:10.1016/j.ejca.2008.10.026.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. Breast Cancer 2005; 1216-27.
11. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619-28. (Pubitemid 44210530)
12. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-9. doi:10.1200/JCO.2006.07.3049. (Pubitemid 46797957)
13. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-65. (Pubitemid 47618607)
14. Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009; 27: 439-45. doi:10.1200/JCO.2008.17.2742.
15. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38(Suppl 5): S60-5. doi:10.1016/S0959-8049(02)80604-9.
16. Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010; 116: 5126-37. doi:10.1002/cncr.25267.
17. Reichardt P, Blay JY, Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 2010; 10: 221-32. doi:10.1586/era.09.171.
18. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17-21. (Pubitemid 47611603)
19. Sandrasegaran K, Rajesh A, Rushing DA, Rydberg J, Akisik FM, Henley JD. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol 2005; 15: 1407-14. doi:10.1007/s00330-005-2647-7. (Pubitemid 40983524)
20. Kaneta T, Takahashi S, Fukuda H, et al. Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med 2009; 23: 459-64. doi:10.1007/s12149-009-0257-1.
21. Da Ronch T, Modesto A, Bazzocchi M. Gastrointestinal stromal tumour: spiral computed tomography features and pathologic correlation. Radiol Med 2006; 111: 661-73. doi:10.1007/s11547-006-0064-x. (Pubitemid 44426751)
22. Lee MW, Kim SH, Kim YJ, et al. Gastrointestinal stromal tumor of the stomach: preliminary results of preoperative evaluation with CT gastrography. Abdom Imaging 2008; 33: 255-61. doi:10.1007/s00261-007-9253-x. (Pubitemid 351537879)
23. Bechtold RE, Chen MY, Stanton CA, Savage PD, Levine EA. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 2003; 28: 808-14. (Pubitemid 37351748)
24. Dudeck O, Zeile M, Reichardt P, Pink D. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2011; 22: 1828-33. doi:10.1093/annonc/mdq696.
25. Schramm N, Schlemmer M, Englhart E, et al. Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: initial results. Curr Pharm Biotechnol 2011; 12: 547-57. doi:10.2174/ 138920111795164066.
26. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005; 32: 153-62. doi:10.1007/s00259-004-1633-7. (Pubitemid 40248485)
27. Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 2005; 25: 4591-4. (Pubitemid 41729517)
28. Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response-an AGITG study. Oncology 2005; 69: 326-32. doi:10.1159/000089765. (Pubitemid 41752801)
29. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 2007; 189: W324-30. doi:10.2214/AJR.07.2496.
30. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20. doi:10.1016/S0959-8049(03)00073-X. (Pubitemid 37297757)
31. Amano M, Okuda T, Amano Y, Tajiri T, Kumazaki T. Magnetic resonance imaging of gastrointestinal stromal tumor in the abdomen and pelvis. Clin Imaging 2006; 30: 127-31. doi:10.1016/j.clinimag.2005.09.025. (Pubitemid 43267628)
32. Tang L, Zhang XP, Sun YS, et al. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. Radiology 2011; 258: 729-38. doi:10.1148/radiol. 10100402.
33. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-4. doi:10.1200/JCO.2006.07.3411. (Pubitemid 46797958)
34. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-78. doi:10.1093/annonc/mdi127. (Pubitemid 40613322)
35. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8. doi:10.1097/00000658-200001000- 00008. (Pubitemid 30043939)
36. Horton KM, Juluru K, Montogomery E, Fishman EK. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. J Comput Assisted Tomogr 2004; 28: 811. doi:10.1097/00004728-200411000-00014.
37. Trent JC, Ramdas L, Dupart J, et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 2006; 107: 1898-908. doi:10.1002/cncr.22214. (Pubitemid 44582961)
38. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. doi:10.1016/S0959-8049(99)00229-4.
39. Chen G, Ma DQ, He W, Zhang BF, Zhao LQ. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008; 14: 5738-43. doi:10.3748/wjg.14.5738.
40. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009; 15: 5902-9. doi:10.1158/1078-0432.CCR-09-0482.